

PRODUCT INFORMATION



4-ANPP

Item No. 39715

CAS Registry No.: 21409-26-7

Formal Name: N-phenyl-1-(2-phenylethyl)-4-piperidinamine

Synonyms: 4-Aminophenyl-1-phenethylpiperidine,
4-Anilino-N-phenethylpiperidine,
Despropionyl fentanyl

MF: $C_{19}H_{24}N_2$


FW: 280.4

Purity: $\geq 95\%$

Supplied as: A solid

Storage: -20°C

Stability: ≥ 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Description

4-ANPP (Item No. 39715) is an analytical reference standard categorized as an opioid metabolite and a precursor in the synthesis of fentanyl (Item Nos. ISO60197 | 22659 | 14719) and other opioids.¹⁻⁵ 4-ANPP is a metabolite of acetyl fentanyl (Item Nos. ISO60128 | ISO00128), butyryl fentanyl (Item Nos. 19734 | 14728), furanyl fentanyl (Item Nos. 19633 | 18705), acrylfentanyl (Item Nos. 23060 | 19312), and fentanyl.¹⁻⁴ It has also been found as an impurity in illicit fentanyl preparations.⁶ 4-ANPP is regulated as a Schedule II compound in the United States. This product is intended for research and forensic applications.

References

1. Watanabe, S., Vikingsson, S., Roman, M., *et al.* *In vitro* and *in vivo* metabolite identification studies for the new synthetic opioids acetylfentanyl, acrylfentanyl, furanylfentanyl, and 4-fluoro-isobutyrylfentanyl. *AAPS J.* **19(4)**, 1102-1122 (2017).
2. Labroo, R.B., Paine, M.F., Thummel, K.E., *et al.* Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: Implications for interindividual variability in disposition, efficacy, and drug interactions. *Drug Metab. Dispos.* **25(9)**, 1072-1079 (1997).
3. Melent'ev, A.B., Kataev, S.S., and Dvorskaya, O.N. Identification and analytical properties of acetyl fentanyl metabolites. *J. Anal. Chem.* **70(2)**, 216-224 (2015).
4. Steuer, A.E., Williner, E., Staeheli, S.N., *et al.* Studies on the metabolism of the fentanyl-derived designer drug butyrylfentanyl in human *in vitro* liver preparations and authentic human samples using liquid chromatography-high resolution mass spectrometry (LC-HRMS). *Drug Test Anal.* **9(7)**, 1085-1092 (2017).
5. Pease, J.P., LePine, A.J., and Smith, C.M. Methods for preparing fentanyl and fentanyl intermediates. *Patent Application Publication US2013/0281702A1*, (2013).
6. Lurie, I.S., Berrier, A.L., Casale, J.F., *et al.* Profiling of illicit fentanyl using UHPLC-MS/MS. *Forensic Sci. Int.* **220(1-3)**, 191-196 (2012).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/02/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM